← All trials
NCT05169671
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2022
- Primary completion
- Dec 12, 2022
- Completion date
- Dec 12, 2022
- First posted
- Dec 27, 2021
- Last posted
- Aug 31, 2022
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Athira PharmaLead sponsor
- BiotrialCollaborator
- Alturas Analytics, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.